We have investigated this problem by analysing prospectively the effects of anticonvulsant treatment in all neonates treated for convulsions in our regional referral unit during a two year period. We specifically looked at the response of clinical and EEG seizure activity to anticonvulsant treatment and its association with later neurological outcome.
Continuous electroencephalographic (EEG) monitoring has identified persistent EEG seizure activity in many infants in whom clinical signs are either undetected or may stop in response to treatment. 1 2 This raises the possibility that many such infants may be failing to receive optimal or adequate anticonvulsant treatment.
Before treatment for EEG detected seizures without clinical signs is contemplated, more critical evaluation of present neonatal anticonvulsant treatment is needed, particularly in view of the potential adverse effects: 7 We have investigated this problem by analysing prospectively the effects of anticonvulsant treatment in all neonates treated for convulsions in our regional referral unit during a two year period. We specifically looked at the response of clinical and EEG seizure activity to anticonvulsant treatment and its association with later neurological outcome.
Patients and methods
During a two year period, 275 infants were recruited to a prospective evaluation of continuous EEG recording with the four channel Oxford Medilog monitor for the diagnosis of neonatal seizures. 2 Thy 55 infants in whom EEG seizure activity was diagnosed form the study group for this report.
During this time clinical seizures were treated initially with a single dose of one of several anticonvulsant drugs at the discretion of the clinician in the following sequence and dosage until response occurred: phenobarbitone (20 mg/kg intravenously); paraldehyde (0.3 ml/kg per rectum, or 1-3 ml/kg/ hour of a 5% intravenous infusion in 5% dextrose); phenytoin (20 mg/kg intravenously); or diazepam (0.25 mg/kg intravenously). Plasma phenobarbitone concentrations were only measured for clinical reasons.
Decisions about the initiation, timing, and continuation of treatment were made independently by the neonatologists who were not given any results of EEG mQnitoring unless they specifically requested information about a particular child.
EEG recordings were made using the Oxford Medilog 4-24 continuous four channel monitor, according to the method described by Eyre et al. ' Two channels were allocated to EEG, using silver/ silver chloride electrodes applied with collodion in the F4-P4 and F3-P3 positions (impedances <5 kohms), one channel to electrocardiography and the fourth channel to either monitoring of respiration, or use as a time-event marker.
Each 24 hours of data was recorded on standard C-120 cassette tape and reviewed on the visual display unit of the Medilog system at 20 and 60 times the normal speed at scales of 1-5 and 3 0 cm/s. A compressed transcription for further analysis was made at 6 cm/minute, using a Siemens 8 ElemaSchonander ink jet recorder.
EEGs were analysed in relation to normal standards for gestational age established from previous studies using standard EEG (TABLE 4) The 31 treated and 24 untreated infants differed in several respects. The treated group, with the exception of one infant, had clinical signs and EEG seizures. The exception was a baby boy who was paralysed for ventilation and was treated after a specific request for EEG data from his clinician. In the untreated group only two infants had clinical seizures, and these were not treated because they rapidly resolved. The treated group were also generally more mature (table 4) .
Clinical neurological outcome did not differ significantly between the treated and untreated group. The incidence of normal outcome and major abnormality in survivors was similar (table 5) . There were more infants with transient dystonia in the untreated group, which also had a lower mortality.
In an attempt to compare the two groups further, infants were subdivided by background EEG appearances so that those with roughly equivalent degrees of cerebral functional disturbance could be compared. All 27 infants with severe background EEG abnormalities (categories 2b and 3), of whom 20 were treated and seven were not untreated, either died or survived with major neurological abnormalities. Nineteen had lesser degrees of background abnormality, but there was no significant difference in outcome between the eight infants who were treated and the 11 who were not.
Outcome in the nine infants who had normal 
background EEG activity was more difficult to compare as only two of these were treated, one of whom died and the other who was abnormal. Of the seven untreated infants, two had a normal outcome, three showed only transient dystonia, and the other two survived with major neurological abnormalities.
Discussion
Although widely used in clinical practice, the efficacy of anticonvulsapt drugs in the newborn has never been assessed by controlled trials.19 In this study we found' that the response of neonatal seizures to anticonvulsant drugs was disappointing, and this was especially apparent when the results of continuous EEG monitoring were taken into account. This unexpectedly poor response could be due to population bias in that most of our infants were preterm with major haemorrhagic or ischaemic lesions, and the infants born at full term with hypoxic-ischaemic encephalopathy were largely referrals from other units and thus already preselected for severity.
Poor response to anticonvulsant drugs may be either an intrinsic feature of such lesions in infants of particular states of maturity, or be related to the specific treatment regimen used. The On the basis of these findings, the nature and severity of the underlying cerebral lesions seem to be the main determinants of both the frequency and duration of associated seizure activity and the subsequent neurological outcome of the infant. Its implications for neonatal practice suggest that more critical review is needed of both clinical and nonclinical seizures, of the balance between anticipated benefits of the use of anticonvulsant drugs, and their recognised adverse effects, particularly in infants with established cerebral lesions.
Further research may thus optimally be aimed at management of the primary lesion, including assessment of new agents for limiting its progress, such as glutamate antagonists,27 rather than undertaking exhaustive comparative studies of available anticonvulsant drugs. In any further study, the use of continuous EEG monitoring for accurate diagnosis of seizures and their response to treatment would be essential.
